Figure 1.
The immunoreactivity of the fully human antibody GB235 against HER2. (A) GB235 specifically bound to soluble human HER2 ECD but not to the other human EGFR family receptors. (B) Flow cytometry analysis of GB235 binding to HER2-overexpressing BT-474 cells. MFI: mean fluorescence intensity. GB235 was evaluated for its activity to compete with biotinylated Trastuzumab (C) and biotinylated Pertuzumab. (D) The results are representative of three different experiments and expressed as the mean ± SEM.